To hear about similar clinical trials, please enter your email below
Trial Title:
A Virtual, Group-Based, Expressive Writing Intervention for Survivors of Adolescent and Young Adult Cancer
NCT ID:
NCT06434402
Condition:
Cancer
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
Non-Randomized
Intervention model:
Single Group Assignment
Primary purpose:
Supportive Care
Masking:
None (Open Label)
Intervention:
Intervention type:
Behavioral
Intervention name:
Behavioral Intervention
Description:
Write about cancer experiences
Arm group label:
Emerging adults (ages18-25 years)
Arm group label:
General group (ages 18-39 years)
Arm group label:
Young adults (ages 26-39 years)
Other name:
Behavior Condition Therapy
Other name:
Behavior Modification
Other name:
Behavior or Life Style Modifications
Other name:
Behavior Therapy
Other name:
Behavioral Treatment
Summary:
To learn more about the experiences of adolescent and young adult cancer survivors and
investigate whether a group-based writing intervention can help to improve quality of
life of adolescent and young adult cancer survivors.
Detailed description:
Primary Objective:
To evaluate the feasibility of a virtual, group-based expressive writing intervention for
survivors of adolescent and young adult cancer.
Secondary Objective:
To preliminarily assess the impact of the study for cancer survivors.
Criteria for eligibility:
Criteria:
Inclusion criteria:
- Age 15-39 years at cancer diagnosis
- Age 18-39 years at study entry
- Within 5 years of diagnosis of stage II-IV cancer
- Completed active treatment (participants receiving maintenance therapy remain
eligible)
- No evidence of disease
- Can speak, read, and write in English.
Exclusion criteria:
- Nonmelanoma skin cancer
- Major mental health disorder (e.g., schizophrenia or bipolar disorder [determined
from patient records or self-disclosure])
- No internet access.
Gender:
All
Minimum age:
18 Years
Maximum age:
39 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
MD Anderson Cancer Center
Address:
City:
Houston
Zip:
77030
Country:
United States
Status:
Recruiting
Contact:
Last name:
Qian Lu, MD,PHD
Phone:
713-745-8324
Email:
qlu@mdanderson.org
Investigator:
Last name:
Qian Lu, MD,PHD
Email:
Principal Investigator
Start date:
May 22, 2024
Completion date:
September 1, 2026
Lead sponsor:
Agency:
M.D. Anderson Cancer Center
Agency class:
Other
Collaborator:
Agency:
National Cancer Institute (NCI)
Agency class:
NIH
Source:
M.D. Anderson Cancer Center
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06434402
http://www.mdanderson.org
